Engflag

Rizin

Quick links to important sections

Rizin

Rizin_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rizin

Rizin is a synthetic medicinal preparation used for systemic anti-allergic relief, which belongs to the class of second-generation antihistamines. The drug's identity is defined by its core active substance, Cetirizine Dihydrochloride, a compound formulated for administration primarily through the oral route.

Quick Facts: Rizin (Cetirizine)

Property Description
Active ingredient Cetirizine Dihydrochloride
Form Oral Tablet, Syrup, Solution
Pharmacological class H1-receptor Antagonist
Common use Systemic Anti-allergic Relief
Origin Synthetic (Piperazine derivative)

The Definitive Identity of Rizin: Active Substance and Origin

Rizin is a preparation containing the single active ingredient Cetirizine Dihydrochloride, which is responsible for the drug's therapeutic effects. This substance is entirely synthetic in origin and is chemically classified as a derivative of the Piperazine structure. The preparation is designed for systemic use, meaning the active substance is absorbed into the bloodstream to act throughout the body.

Pharmacological Classification and General Purpose

Rizin is precisely classified as an H1-receptor antagonist, a category synonymous with its role as an antihistamine. Its general purpose is to provide relief by selectively blocking the action of histamine, a natural chemical messenger that the body releases during an allergic reaction. Cetirizine is recognized for its ability to relieve symptoms caused by environmental allergens. This medicine helps ease discomfort by interrupting the body's reaction to common allergic triggers. The second-generation nature of the drug is clinically recognized for offering high selectivity for peripheral H1 receptors, minimizing the ability to cross the blood-brain barrier. A typical use scenario involves alleviating symptoms such as a runny nose or watery eyes caused by seasonal allergic rhinitis.

Available Preparations and Dosage Forms

Rizin is supplied in several forms suitable for oral administration, offering flexibility to meet various patient needs. The common forms include the film-coated oral tablet and the liquid syrup or solution. The preparation is also available in specialized formats, such as the oral dispersible tablet, which is designed to break down rapidly in the mouth for easier consumption, especially by individuals who have difficulty swallowing conventional solid forms.

What side effects are possible with Rizin?

Possible Side Effects and Safety Information

The safety profile of Rizin (Cetirizine Dihydrochloride) is formally classified by regulatory authorities based on the frequency and the System Organ Class (SOC) affected. This information is derived from documented clinical trials and post-marketing surveillance data.

Adverse Reaction Frequencies

Common adverse reactions (affecting more than 1 in 100 people) primarily involve the Nervous System and General Disorders, and may include somnolence (drowsiness), fatigue, headache, dizziness, and dry mouth. Uncommon effects include agitation and paresthesia.

Rare and Very Rare documented reactions, though infrequent, include more serious events such as hypersensitivity or anaphylactic shock (Very Rare Immune System Disorders), convulsions, tremor, and abnormal hepatic function (Rare).

Classification Examples of Affected Systems/Effects
Common Nervous System, General Disorders, Gastrointestinal (e.g., somnolence, fatigue, dry mouth)
Rare/Very Rare Immune System, Hepatobiliary, Cardiac (e.g., anaphylactic shock, hepatic function abnormal)

Population-Specific Safety and Restrictions

Official labeling includes specific safety considerations. Clearance of the active substance is reduced in patients with impaired renal function. Consequently, caution and possible dose adjustment are required for these individuals and for older adults, where renal function is often diminished. Rizin is contraindicated in patients with severe renal impairment.

Furthermore, caution is advised for patients with predisposing factors for urinary retention or those with epilepsy due to the potential for increased risk. A risk of severe pruritus (itching) has also been documented to occur days after discontinuation of long-term use.

Overdose and Emergency Response

The official regulatory profile for Rizin overdose describes specific signs that typically manifest following ingestion of doses at least five times the recommended daily limit. Documented presentations primarily involve the Central Nervous System (CNS) and effects suggesting anticholinergic activity. CNS manifestations include somnolence, stupor, confusion, dizziness, and fatigue. Autonomic signs may include tachycardia (fast heart rate) and urinary retention. Gastrointestinal effects such as diarrhea and abdominal pain are also noted in official regulatory summaries.

Immediate medical attention is required if a severe reaction is suspected. Authorities mandate contacting a Poison Control Center or emergency services at once. Urgent medical help must be sought if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened, as these are classified as life-threatening situations.

The management of Rizin overdose is exclusively symptomatic and supportive, as there is no specific antidote known for the active substance. Procedures such as gastric lavage may be considered in the initial hours following acute ingestion. Rizin is not effectively removed by dialysis.

Special considerations exist for populations with compromised drug elimination. Regulatory information highlights that geriatric patients and individuals with impaired kidney function experience reduced clearance and a prolonged half-life, increasing the risk of systemic drug exposure in the event of an overdose.

Therapeutic Uses of Rizin

Rizin is applied across domains where additional symptomatic support is needed, primarily for conditions characterized by periods of heightened symptoms related to inflammatory or irritative states. Rizin is commonly used for the management of key allergic indications.

The medication helps address symptom clusters associated with allergic rhinitis, Chronic Idiopathic Urticaria (persistent hives), and allergic conjunctivitis. It is often used during phases when symptoms become more noticeable, such as during peak seasonal exposure or for the year-round management of indoor allergens. In practice, Rizin is relevant for easing symptoms related to physical discomfort like recurrent sneezing, bothersome runny nose (rhinorrhea), and intense pruritus (itching). This support contributes to easing the overall symptom load and assists with maintaining functional stability when symptoms interfere with routine activities.

“Rizin is commonly used to help patients cope more steadily with symptom fluctuations associated with common allergic reactions.”

Quick Fact: Symptomatic Support Focus
Allergic Rhinitis: Helps ease nasal and ocular irritation.
Chronic Urticaria: Supports the easing of persistent hives and itching.
Benefit: Contributes to easing the overall symptom load.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Rizin

Rizin (Cetirizine Dihydrochloride) eligibility is defined by regulatory bodies, establishing specific restrictions and contraindications based on patient population. This section outlines who is allowed, restricted, or prohibited from using the medicine.

Absolute Contraindications

Rizin is contraindicated and must not be used by individuals with a known hypersensitivity or allergic reaction to Cetirizine Dihydrochloride, any of its components, or the related antihistamine Hydroxyzine.

Age-Group Eligibility

The medicine is approved for use in adults and adolescents (12 years), and children 6 years. Use in children under six years old is generally restricted to specific formulations and may require professional supervision. For older adults (65 years), caution is advised, and dose adjustments may be necessary due to potential changes in renal clearance.

Organ Function and Physiological Restrictions

Use is restricted in patients with impaired renal function (moderate to severe) or hepatic impairment, as dose adjustment is required. The medicine is not recommended for patients with severe renal impairment (e.g., Creatinine Clearance < 10 mL/min).

Use during pregnancy is documented as allowable only if clearly needed. Rizin is not recommended for use by nursing mothers, as the active substance is known to be excreted into human breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rizin (rizatriptan) can interact with several medicinal products and categories, necessitating specific restrictions based on potential pharmacological and metabolic effects.

Contraindicated Combinations

The following combinations are strictly prohibited due to the risk of serious adverse reactions, including increased blood pressure or the potentially life-threatening Serotonin Syndrome:

  • Monoamine Oxidase (MAO-A) Inhibitors: Since Rizin is primarily metabolized by MAO-A, co-administration inhibits its breakdown, leading to significantly increased plasma concentrations of Rizin. It is contraindicated for use with MAO-A inhibitors or within two weeks of discontinuing MAO-A inhibitor therapy.
  • Other 5-HT1 Agonists (Triptans): Simultaneous use with other triptans is contraindicated due to an additive risk of vasospasm (constriction of blood vessels). Dosing must be separated by at least 24 hours.
  • Ergotamine-Containing Medications: Use with ergotamine or ergot derivatives is also contraindicated for 24 hours before or after Rizin administration due to the risk of cumulative vasoconstrictor effects.

Use Requiring Dose Modification

  • Propranolol: This beta-blocker has been shown to increase Rizin plasma concentrations by approximately 70% in clinical studies. This interaction is believed to be due to propranolol interfering with Rizin's MAO-A-mediated metabolism. Patients taking propranolol are restricted to a lower single dose of Rizin, and the maximum daily dose is also reduced.

Mechanism of Action

How Rizin Works: Mechanistic Domains

Selective H1 Receptor Blockade and Signal Suppression

This mechanism acts within domains involving receptor-mediated signaling, where the active ingredient engages the peripheral Histamine H1 receptor as a high-affinity antagonist. This highly selective molecular action rapidly suppresses the histamine signaling pathway, thereby inhibiting the activation of sensory nerves and the downstream effects on vascular endothelial cells.

Modulation of Vascular Permeability and Endothelial Function

The core mechanism modulates key pathways associated with histamine-driven physiological responses by focusing on vascular integrity. The H1 blockade stabilizes the cell-to-cell junctions of the capillary endothelium, which restricts the influence of excessive histamine activity. This directly restricts the leakage of fluid and proteins from the bloodstream, leading to a predictable physiological adjustment that modulates localized tissue fluid accumulation and extravasation.

Inhibition of the Late-Phase Inflammatory Cascade

Beyond immediate receptor antagonism, the drug engages mechanisms that regulate overactive or dysregulated cellular processes, specifically within the later stages of immune activation. It is relevant in contexts involving the recruitment of immune cells by suppressing the chemotaxis and accumulation of inflammatory cells, such as eosinophils, thereby influencing the dynamics within the targeted inflammatory pathways.

Dosage and Administration Information

Rizin (Cetirizine Dihydrochloride) is administered for systemic use primarily via the oral route, available as tablets, capsules, and solutions, or as an intravenous (IV) injection in settings for acute conditions. A common usage pattern for adults and adolescents (ge 12 years) involves a dose of 10 mg taken once daily. In cases of milder symptoms, a starting dose of 5 mg once daily may be utilized, though the maximum daily intake is capped at 10 mg. Oral doses may be taken with or without food for convenience. If a dose is missed, the typical practice is to skip the missed dose and continue with the next scheduled dose at the regular time; a double dose is not taken to compensate.

The intravenous preparation is reserved for acute situations and is administered as a 10 mg injection once every 24 hours. The procedural requirement for this route is administration as an intravenous push delivered over a period of 1 to 2 minutes. Specific dose adjustments are utilized for certain patient populations. For patients with moderate renal impairment, the dose of the oral formulation is typically reduced to 5 mg once daily due to the drug's primary clearance mechanism. Furthermore, the 10 mg tablet formulation is generally not used for dosing in children younger than six years of age.

Recent Clinical Evidence

Rizin: Research Evidence / Overview of Studies

The research evidence for Rizin (Cetirizine Dihydrochloride) comes mainly from formal clinical evaluations, including Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. This overview is purely descriptive and summarizes what these authoritative studies monitored and reported, without offering any clinical advice or guidance.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

The research examined Rizin in contexts involving managing Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR), relying on a large number of RCTs. These studies were used to evaluate Rizin for conditions characterized by fluctuating manifestations of allergies. Researchers focused on outcomes related to systemic or functional imbalance, specifically measuring changes in the Total Symptom Score (TSS), which is used in research exploring how symptoms change over time.

Studies monitored and described how symptoms evolved in the observed populations in research scenarios, including those with placebo or active comparator groups. Research highlights changes measured during the study period, particularly regarding patient-reported outcomes describing perceived discomfort. Data for the durability of the observed symptomatic pattern over many consecutive seasons or years of use are not comprehensively detailed in the primary regulatory records.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

For Chronic Idiopathic Urticaria (CIU), the evidence stems from controlled studies used in research contexts involving fluctuating or unstable symptoms. The research monitored outcomes related to physical discomfort, primarily evaluating changes in the severity and frequency of weals (hives) and the intensity of pruritus (itching). The reported outcomes documented patterns related to weal count and size, and recorded changes in the self-reported intensity of itching in the study populations at the standard licensed dose.

Evidence in Special Populations and Uncertainties

Rizin was evaluated in specific age groups, including pediatric patients (children and infants) across different age cohorts, with evidence highlighting that Rizin was studied for symptom assessment in children as young as six months in some contexts. Studies also monitored older adults, noting that the rate at which the active substance is cleared may be slower compared to younger adults.

Despite the comprehensive nature of the evidence for core licensed uses, certain areas of research still present limitations. Research highlights what is known—and what is still uncertain—regarding use beyond the standard doses; for refractory CIU, follow-up durations were limited, meaning research does not determine whether an individual will respond similarly to these higher doses over time.

Frequently Asked Questions (FAQ)

Common questions about Rizin (FAQ)

Q: Is Rizin a sedating or non-drowsy antihistamine?

Official product information states that drowsiness (somnolence) is a commonly reported side effect with the use of Rizin. This effect may be increased by concurrent use of alcohol or other sedatives and tranquilizers. Official labeling includes warnings that individuals should be cautious when driving or operating machinery until they are aware of the medication's effect on them.

Q: How long does it take for Rizin to start working?

According to official information, the therapeutic effects of the active substance typically begin within 20 to 60 minutes after an oral administration. The concentration of the active substance in the blood typically reaches its peak level around one hour after it is taken.

Q: Can I drink alcohol while taking Rizin?

Official product information advises against the use of alcoholic drinks while taking this medication. This is because alcohol may increase the drowsiness caused by Rizin, which can potentially lead to greater impairment in thinking and judgment.

Q: Can I take Rizin with other allergy medicines?

Official product information notes that individuals should consult with a healthcare provider if they are currently taking tranquilizers or sedatives, as these can increase drowsiness when combined with Rizin. The label also advises caution when combining Rizin with any other medication that causes sleepiness. It is important to note that Rizin is specifically contraindicated (not allowed) for use with other 5-HT1 agonists (triptans) and MAO-A inhibitors.

Q: What should I do if I miss a dose of Rizin?

Official regulatory instructions indicate that a patient may take the forgotten dose as soon as they remember it. However, if it is nearly time for the next scheduled dose, the missed dose is typically skipped, and the patient resumes their normal schedule. It is specifically stated that a double dose should not be taken to compensate for a missed dose.

Q: Are there any specific dietary restrictions to consider when taking Rizin?

Regulatory documents indicate that Rizin can be taken with or without food. While food may affect the time it takes for the drug to reach its maximum concentration in the blood, it does not significantly affect the overall absorption of the medication.

How should Rizin be stored and disposed of?

How to Store and Dispose of Rizin (Cetirizine Dihydrochloride)

The storage and disposal of Rizin must adhere strictly to the conditions specified in official regulatory labeling.

Storage Requirements

Rizin tablets and solution must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions. The product must be kept in its original container, tightly closed, and protected from excess heat and moisture. To prevent accidental ingestion, it is a mandatory requirement to store the medicine out of the sight and reach of children and to securely lock any safety caps.

Disposal Instructions

Expired or unused Rizin should be disposed of using a drug take-back program or an authorized collection site. If a take-back option is unavailable, the product may be mixed with an unappealing substance (like dirt), sealed in a container, and placed in the household trash. It is prohibited to dispose of Rizin by flushing it down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rizin found in:

A-Z Index: